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African swine fever virus (ASFV) causes a lethal haemorrhagic disease of pigs. There are conﬂicting
reports on the role of interferon in ASFV infection. We therefore analysed the interaction of ASFV with
porcine interferon, in vivo and in vitro. Virulent ASFV induced biologically active IFN in the circulation of
pigs from day 3-post infection, whereas low virulent OUR T88/3, which lacks genes from multigene
family (MGF) 360 and MGF505, did not. Infection of porcine leucocytes enriched for dendritic cells, with
ASFV, in vitro, induced high levels of interferon, suggesting a potential source of interferon in animals
undergoing acute ASF. Replication of OUR T88/3, but not virulent viruses, was reduced in interferon
pretreated macrophages and a recombinant virus lacking similar genes to those absent in OUR T88/3 was
also inhibited. These ﬁndings suggest that as well as inhibiting the induction of interferon, MGF360 and
MGF505 genes also enable ASFV to overcome the antiviral state.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
African swine fever (ASF) is a viral haemorrhagic disease of
domestic and wild pigs (both Sus scrofa). Virulent strains of ASF
virus (ASFV) can cause up to 100% mortality, while low virulent
strains can cause inapparent infections from which the animals
develop immunity to related virulent strains. The natural hosts for
the virus are warthogs (Phacochoerus aethiopicus) and bushpigs
(Potamochoerus porcus), which do not develop clinical signs of
disease (Anderson et al., 1998; Oura et al., 1998; Thomson, 1985;
Thomson et al., 1980). In addition, ASFV can infect soft ticks of the
family Ornithodoros (Boinas et al., 2011; Diaz et al., 2012), which
can contribute to transmission of the virus in the ﬁeld. Controlling
outbreaks of ASFV can prove to be difﬁcult, as evidenced by the
continuing problems in the Russian Federation, and surrounding
European countries. Understanding the immune response to ASFVr Inc. This is an open access article
Road, Pirbright, Surrey GU24
.L. Netherton).is of importance to delivering an effective vaccine against
the virus.
ASFV is the only member of the Asfarviridae family, and is
grouped within the nucleo-cytoplasmic large DNA viruses. ASFV is
a non-segmented, linear, double-stranded DNA virus with a gen-
ome length ranging from 170 to 193 kilo base pairs which codes
for between 151 and 167 open reading frames (Chapman et al.,
2008; de Villiers et al., 2010; Dixon et al., 2013; Yáñez et al., 1995).
Length variations in the genome occur at the termini, due to
insertions and deletions of genes within ﬁve multigene families
(MGF). The function of the genes within these families is currently
unknown, and they do not share sequence identity with other
known genes. However, previous work suggests that genes within
MGF360 and MGF505 (also referred to as MGF530) are important
in determining host range (Burrage et al., 2004; Zsak et al., 2001)
and are involved in inhibition of interferon (IFN) induction (Afonso
et al., 2004).
Type I IFN is a crucial component of the innate response to viral
infection (Randall and Goodbourn, 2008). Components of patho-
gens such as nucleic acids are recognised by intracellular and
extracellular receptors that induce a complex signal transduction
pathway that leads to the secretion of type I IFN; these cytokinesunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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genes (Der et al., 1998), leading to the establishment of an antiviral
state within neighbouring cells and subsequent restriction of fur-
ther rounds of viral replication. IFNβ is induced in most cell types,
whereas IFNα shows a more restricted pattern of induction;
notably, plasmacytoid dendritic cells (pDCs), also called natural
interferon producing cells, are capable of producing large amounts
of IFNα due to constitutive expression of the transcription factor
IRF7. In addition to directly restricting viral replication, IFNα/β up-
regulates surface expression of MHC class I and II, activates den-
dritic cells (DCs) and natural killer cells (Carrero, 2013; Nguyen et
al., 2002), and can inﬂuence T-cell function (Huber and Farrar,
2011). As such, IFN has an important role to play in both innate
and adaptive immunity to pathogens.
ASFV primarily replicates in monocytes and macrophages,
although other cells can be infected at later time points following
infection of pigs (Pérez et al., 1994; Ramiro-Ibáñez et al., 1995).
Avirulent/low-virulent strains, that lack genes from MGF360 and
MGF505, induce the expression of IFN during infection ofTime post infection (day)
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Fig. 1. IFN in the serum of pigs infected with ASFV Georgia 2007/1, OUR T88/1 or OUR T8
Large White-Landrace pigs inoculated intramuscularly with 104 HAD50 of virulent Georg
using the MxA-CAT assay (a and b). Results were expressed as the mean of IFN IU/ml of
was determined using a porcine IFNα ELISA (c). Results were expressed as the mean of IFN
Results were expressed as the mean of IFNβ pg/ml of duplicate samples. Serum was colle
OUR T88/3 (f and g). Biologically active IFN was determined using the MxA-CAT assay (f).
(log10) in Large White Landrace pigs inoculated with virulent Georgia 2007/1 (e) or NIH
correspond to animal numbers.macrophages in vitro (Afonso et al., 2004; Gil et al., 2008), whereas
virulent ASFV strains do not (Afonso et al., 2004; Gil et al., 2008;
Zhang et al., 2006). However, IFNα and IFNβ have been detected in
the serum of pigs infected with virulent Georgia 2007/1 (Karalyan
et al., 2012), demonstrating that while virulent ASFV does not
induce IFN in vitro, it does induce it in vivo.
There are conﬂicting reports on the role of IFN during ASFV
infection. Replication of two virulent ASFV strains was reduced in
porcine macrophages pretreated with bovine IFNα (Esparza et al.,
1988). A similar observation was seen in Vero cells pretreated with
human IFNα and then infected with cell culture-adapted ASFV
BA71V (Paez et al., 1990). In contrast, induction of IFN in porcine
macrophages by polyI:C did not affect the replication of either the
virulent Kirawira or the attenuated Uganda strain of ASFV
(Wardley et al., 1979). These apparent discrepancies in the sensi-
tivity of ASFV to IFN, coupled with the differences seen between
the induction of IFN in vitro and in vivo, led us to re-examine this
important host-pathogen interaction. We compared the inductionC924
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Fig. 2. Replication of ASFV strains lacking genes from MGF360 and MGF505 in the
presence of porcine IFNα. Alveolar macrophages were infected with the indicated
ﬁeld ASFV strains (a) and/or recombinant ASFV strains (b) as well as suid herpes-
virus 1 (SuHV-1) at an MOI of 0.1. Cells were pretreated for 24 h prior to infection
with 2000 IU/ml recombinant porcine IFNα (grey bars) or left untreated (white
bars). Virus yields were determined 48 h post infection on alveolar macrophages.
Titres are shown as the mean log10TCID50/ml7standard deviation of triplicate
wells and are representative of three independent experiments.
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and the effect of porcine IFNα on ASFV replication in vitro.2. Results
2.1. Characterisation of the systemic IFN response to infection of pigs
with virulent and low virulent ASFV
Serum levels of IFN were determined in pigs infected either
with the virulent Georgia 2007/1, or the low virulent OUR T88/3
strains of ASFV using a bioassay that measures CAT expression
controlled by the promoter of the IFN-stimulated gene MxA (Fray
et al., 2001), and by IFNα- and IFNβ-speciﬁc ELISAs. Following
infection with Georgia 2007/1, the highest levels of IFN activity
were observed on days 3 to 4 post-infection (p.i.) (Fig. 1a). The
quantity of biologically active IFN measured at these time points
varied considerably between pigs, from approximately 200 IU/ml
in pig AP55 to 1000 IU/ml in pig AP57. Sera from three pigs
infected with virulent OUR T88/1 (Abrams et al., 2013) contained
similar levels of biologically active IFN as the animals infected with
Georgia 2007/1, ranging from 100 IU/ml to nearly 600 IU/ml
between day 3 and 5 p.i. (Fig. 1b). Pigs infected with virulent
Georgia 2007/1 produced IFNα and IFNβ proﬁles similar to those
seen in previous studies (Karalyan et al., 2012). IFNα peaked at day1 or 2 p.i., measuring between 130 and 230 pg/ml (Fig. 1c), and
then decreased until the end of the study. IFNβwas detected in the
serum later during infection than IFNα and the trend was for a
general increase in IFNβ as disease progressed. The highest
amounts of IFNβ detected were on the ﬁnal day (day 7–8 p.i.) of
the experiment and ranged from 30 to 52 pg/ml (Fig. 1d). Viraemia
was ﬁrst detected on day 3 p.i. in pigs infected with Georgia 2007/
1 and increased until day 5 when virus levels plateaued between
106 and 107 genome copies per ml (Fig. 1e). The appearance of
circulating IFN preceded the appearance of virus by approximately
one to two days. These data show that infection with virulent ASFV
induces IFN in the circulation, which, in some individuals, reaches
the equivalent of nearly 1000 IU/ml (Fig. 1a). To analyse the IFN
response following infection with low virulent ASFV, six NIH
minipigs and ﬁve outbred pigs were infected with the OUR T88/3
strain. Biologically active IFN was not detected in the serum of any
of the NIH minipigs (Fig. 1f) or outbred pigs (Supplemental Fig. 1)
infected with OUR T88/3. In contrast to pigs infected with Georgia
2007/1, only very low levels (o102 genome copies/ml) of circu-
lating virus were detected in four of the OUR T88/3-infected
minipigs (Fig. 1g). These data show a clear difference in vivo in the
induction of IFN in pigs infected with virulent and low virulent
ASFV. Higher levels of biologically active IFN in pigs infected with
Georgia 2007/1 appeared to coincide with the appearance of vir-
aemia at day 3 (Fig. 1e). Importantly viraemia increased between
day 3 and 5 despite the presence of a signiﬁcant amount of bio-
logically active IFN.
2.2. Replication of virulent ASFV is not inhibited by IFNα
The ﬁnding that virulent ASFV continues to replicate in the
presence of circulating IFN does not correlate with previously
published in vitro data demonstrating that virulent ASFV is sen-
sitive to the antiviral effects of IFNα (Esparza et al., 1988). In order
to investigate the antiviral effects of IFN on ASFV further, porcine
alveolar macrophages, pretreated for 24 h with recombinant por-
cine IFNα, were infected with virulent ASFV isolates BA71, Georgia
2007/1 and OUR T88/1, the low virulent OUR T88/3 isolate, as well
as suid herpesvirus 1 (SuHV-1 also referred to as pseudorabies and
Aujesky's disease virus) which is sensitive to porcine IFNα (Cheng
et al., 2006). IFNα did not affect the ability of any of the virulent
ASFV strains tested to replicate in alveolar macrophages. However,
the replication of both OUR T88/3 and SuHV-1 were reduced
approximately 10-fold by pre-treatment of cells with 2000 IU/ml
of recombinant IFNα (Fig. 2a). Similar results were also observed
in macrophage cultures derived from blood monocytes (Supple-
mental Fig. 2). The observation that Georgia 2007/1 and OUR T88/
1 were not inhibited by IFNα in vitro is consistent with our results
showing that these isolates replicate in vivo in the presence of IFN
(Fig. 1), and contrasts with a previous report showing that repli-
cation of virulent BA71 in porcine macrophages was inhibited by
recombinant bovine IFNα (Esparza et al., 1988).
2.3. Role of MGF360 and MGF505 genes in overcoming the antiviral
effects of IFN
In comparison with virulent ASFV, OUR T88/3 lacks ﬁve genes
from MGF360 (MGF360-10L, -11L, -12L, -13L, and -14L) and two
genes from MGF505 (MGF505-1R and -2R) (Chapman et al., 2008).
Recombinant viruses derived from the virulent Pr4 isolate of ASFV
in which genes from MGF360 and MGF505 were deleted (Burrage
et al., 2004) were used to further reﬁne the role of these gene
families in overcoming the antiviral effects of IFN. Pr4Δ35 is a
deletion mutant that lacks the genes that are also absent in OUR
T88/3, as well as an additional MGF360 gene (MGF360-9L).
Pr4Δ3-C1 lacks MGF360-9L, -10L, and -11L; Pr4Δ3-C2 lacks
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Pr4Δ5-2 lacks MGF505-2R. Previous studies have shown that
Pr4Δ35 induces IFNα in porcine macrophages, in vitro, whereas
the parental Pr4 strain does not (Afonso et al., 2004). Replication of
Pr4Δ35 was signiﬁcantly reduced in alveolar macrophages treated0 102 103 104 105
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Our data show that virulent ASFV is able to induce large
amounts of circulating IFN in infected animals. Previous data
shows that virulent ASFV does not induce IFN in porcine macro-
phage cultures and similarly we could only detect biologically
active IFN in the supernatants of macrophages infected with OUR
T88/3 or Pr4Δ35 (Supplemental Fig. 3) Therefore we looked to see
whether IFN is produced by ASFV-infected DCs. Peripheral blood
mononuclear cells (PBMCs) from naïve pigs were depleted of
T-cells, B-cells and monocytes using a cocktail of monoclonal
antibodies in order to enrich for DCs. These negatively-selected
cells were then incubated with virulent OUR T88/1, low virulent
OUR T88/3, CpG or Sendai virus for 24 h. Supernatants from these
cultures were then analysed for IFN activity. An example of the
proportion of PBMCs expressing CD3, CD14 or CD21 following
depletion is shown in Fig. 3a–c. The negatively-selected cell
population comprised 20% CD172aþ cells consisting of both
CD172a high and CD172a low cells. A proportion of the CD172a low
population also expressed CD4 which is characteristic of pDCs
(Fig. 3g) (Calzada-Nova et al., 2010; Summerﬁeld et al., 2003). This
negatively-selected cell population produced large quantities of
biologically active IFN when exposed to both virulent and low
virulent strains of ASFV, as well as to CpG and Sendai virus
(Fig. 3h). IFN was not detected in supernatants from cells incu-
bated in media alone, mock-infected cells (Fig. 3h) or ASFV isolates
incubated for 24 h in the absence of any cells (not shown). These
observations suggest that pDCs may contribute to the high levels
of IFN detected in animals infected with virulent strains of ASFV.3. Discussion
IFN is an important component of the innate response to
infection and many viruses have evolved mechanisms to avoid or
abrogate IFN induction and/or the antiviral state. Previous work
suggested that ASFV was sensitive to the effects of IFN (Esparza et
al., 1988; Paez et al., 1990) and this correlated with the apparent
link between attenuation and the ability to induce IFN in vitro
(Afonso et al., 2004; Gil et al., 2008; Powell et al., 1996; Zhang et
al., 2006). However, recent experiments revealed the presence of
IFN in the serum of animals infected with virulent viruses shed-
ding doubt on this hypothesis (Karalyan et al., 2012). In this study,
we conﬁrm that IFNα and IFNβ are present in the serum of ani-
mals infected with virulent ASFV (Fig. 1c and d) and also demon-
strate the presence of biologically active IFN in the circulation
(Fig. 1a and b). The appearance of IFN in the blood is co-incident
with the appearance of viraemia (Fig. 1e) and appears to correlate
with the appearance of TNFα (Gómez del Moral et al., 1999) and IL-
1β (Salguero et al., 2002). The proﬁle of IFN activity in the serum of
animals infected with virulent ASFV was very similar to that
observed in pigs infected with virulent classical swine fever virus
(CSFV), although IFNβ was not detected in these pigs (Summer-
ﬁeld et al., 2006). The presence of high levels of IFN has been
linked to the depletion of B-and T-cells from the blood of CSFV-
infected pigs and IFN, in combination with TNFα, could contribute
to the lymphopenia observed during acute ASF (Sanchez-Vizcaino
et al., 1981).
The large amount of biologically active IFN in the circulation,
several days before viraemia reached its peak, suggested that IFN
did not inhibit virus replication in vivo. This was inconsistent with
previous studies showing that replication of ASFV was sensitive to
IFN in vitro (Esparza et al., 1988). Our studies did not conﬁrm this
observation and in fact we demonstrated that replication of viru-
lent BA71 was not inhibited in either alveolar (Fig. 2a) or blood-
derived macrophages (Supplemental Fig. 2) treated with porcineIFNα. In our hands, the replication of a number of different viru-
lent ASFV isolates from different genetic backgrounds was not
inhibited by IFN in both macrophage models. Therefore, our
results with virulent ASFV are in agreement with those of Wardley
et al. (1979).
One apparent contradiction in the literature explored here was
the presence of IFN in the serum of pigs with acute ASF (Karalyan
et al., 2012) and the failure of virulent viruses to induce IFN in
macrophages in vitro (Afonso et al., 2004; Gil et al., 2008; Zhang et
al., 2006). This may be simply due to signiﬁcant differences
between the types of macrophages that ASFV infects in vivo and
the tractable porcine macrophage models available in vitro.
Another possibility is that IFN is being secreted by neighbouring
cells in response to signals such as cGAMP(20-50) emanating from
ASFV-infected cells (Ablasser et al., 2013). Alternatively IFN may be
secreted by cells such as DCs in response to ASFV infection. Many
types of DCs can secrete IFN in response to viral infection (O’Keeffe
et al., 2012; Schulte et al., 2015) and pDCs in particular secrete
large quantities of IFN in response to viral infection. A population
of PBMCs enriched for CD4þ/CD172þ cells produced large quan-
tities of IFN when exposed to both virulent and low virulent ASFV.
This is the ﬁrst example of a cell population secreting IFN in
response to virulent ASFV infection and implicates pDCs as a
potential source of the IFN found in the serum of animals under-
going an acute ASF infection. Future experiments should attempt
to deﬁne the types of IFN secreted by these DCs and to further
characterise the DC population responsible in vitro and by deﬁning
IFN secreting cells in vivo.
Low virulent OUR T88/3 showed a 10-fold decrease in titre in
the presence of IFN compared to virulent strains of ASFV. There are
a number of differences between OUR T88/3 and related virulent
viruses that could account for the differing sensitivity to IFN
(Chapman et al., 2008; Portugal et al., 2015). Major differences
include disruption of the EP153R and EP402R genes responsible
for haemadsorption and variations in the number of copies of
MGF110, MGF360 and MGF505. Of particular interest were the
deletion of ﬁve members of MGF360 and two of MGF505 as these
have been linked to the induction of IFN (Afonso et al., 2004).
MGF360 and MGF505 members have no sequence identity with
other cellular or viral proteins. The role of MGF360/505 genes in
sensitivity of ASFV replication were explored further using
recombinant Pr4 strains that lacked different combinations of
these MGF genes. However, whilst Pr4Δ35, a strain lacking a
similar subset of MGF genes to OUR T88/3 was susceptible to IFN,
strains lacking only subsets of these genes were not, suggesting
that no single gene is sufﬁcient to enable ASFV to replicate opti-
mally in the presence of IFNα. One interesting result was that in
our hands Pr4Δ35 replicated as efﬁciently as wild type Pr4 in both
alveolar (Fig. 2b) and blood derived macrophages (Supplemental
Fig. 2b). Previously this deletion mutant has been shown to have a
thousand-fold growth defect in blood derived macrophages (Bur-
rage, et al. 2004). The only differences between our experiments
and the published data is that we cultured macrophages with
porcine serum, whereas Burrage et al. used L929 supernatant and
foetal bovine serum, therefore there may have been differences in
the maturation states of the macrophage cultures. Foetal calf
serum has been linked to reduced virus growth in alveolar mac-
rophages (Bustos, et al., 2002), but it seems unlikely that this
would account for the difference we have observed. OUR T88/3
and recombinant Pr4Δ35, which were sensitive to IFNα, lack both
MGF505-1R and MGF505-2R when compared to virulent strains.
However, the other recombinant Pr4 viruses that were not inhib-
ited by IFN contained one of either MGF505-1R or MGF505-2R.
Therefore, it is possible that efﬁcient ASFV replication in the pre-
sence of IFN requires either MGF505-1R or MGF505-2R, but the
loss of both genes reduces ASFV replication in the presence of IFN.
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the Pr4Δ35 or OUR T88/3 backbone would show which genes are
required for replication in the presence of IFN.
Low virulent OUR T88/3 induced IFN in vitro in DCs, was sen-
sitive to pre-treatment with IFNα, did not induce any detectable
levels of IFN in vivo and can induce robust immunity to related
virulent strains of ASFV (Boinas et al., 2004; King et al., 2011; Oura
et al., 2005). It is possible that induction of IFN in target cells and
or DCs in lymphoid tissues coupled with the sensitivity of OUR
T88/3 to IFN may limit virus replication and hence dissemination
of the virus and therefore the level of circulating IFN induced
in vivo. Nevertheless, the ability of OUR T88/3 to induce IFN in DCs
may be sufﬁcient to activate DCs and natural killer cells as well
inﬂuencing T-cell responses. Both CD8 cells and NK cells play an
important role in protective immunity against ASFV (Leitao et al.,
2001; Oura et al., 2005).4. Methods
4.1. Cells
Porcine primary cells were derived from Large White outbred
pigs typically 4 weeks old. Bone marrow cells were prepared from
femur bones and were maintained in EBSS (Sigma) supplemented
with 10% porcine serum (BioSera) and 100 IU/ml penicillin and
100 mg/ml streptomycin. Alveolar macrophages were prepared by
lung lavage with Ca/Mg-free PBS and maintained in RPMI 1640
medium supplemented with 10% heat-inactivated porcine serum
and 200 IU/ml penicillin and 200 mg/ml streptomycin. Vero and
Madin–Darby bovine kidney (MDBKt2) cells were maintained in
DMEM-HEPES supplemented with 10% heat-inactivated foetal calf
serum and 100 IU/ml penicillin and 100 mg/ml streptomycin. 10 mg/
ml Blasticidin was included with the MDBKt2 cells.
4.2. Antibodies
The following monoclonal antibodies were used for depletion
studies and ﬂow cytometry: anti-CD3 (PPT3, IgG1) (Yang and
Parkhouse, 1996), anti-CD21 (CC51, IgG2b) (Saalmuller, 1996), anti-
CD14 (CCG33, IgG1) (Sopp et al., 1996), anti-CD4 (PT90A, IgG2a;
VMRD, USA), and anti-CD172 (74-22-15; IgG1) (Saalmuller, 1996).
Monoclonals against bovine WC1 (CC39; IgG1, CC15; IgG2a)
(Morrison and Davis, 1991) and bovine CD6 (CC38; IgG2b)
(Letesson and Bensaid, 1991) were used as isotype controls.
4.3. Flow cytometry
1 μg of puriﬁed monoclonal antibody or 15 μl of tissue culture
supernatant was labelled using 5 μl of Zenon antibody labelling
kits (Life Technologies), using Alexa Fluors 488 and R-
Phycoerythrin. 3105 cells were incubated with Live/Deads Fix-
able Near-IR Dead cell stain (Life Technologies), conjugated anti-
bodies, and ﬁxed with 1% PFA prior to acquisition on the LSR
Fortessa (BD Biosciences). Analysis was carried out on FlowJo
software where cells were gated on live, single cells with 99%
viability observed.
4.4. Viruses
The viruses used in these experiments have been previously
described, and include ASFV ﬁeld strains: virulent Georgia 2007/1
(Rowlands et al., 2008), virulent Badajoz 1971 (BA71) (Enjuanes et
al., 1976), virulent OUR T88/1, low virulent OUR T88/3 (Boinas et
al., 2004), and virulent Pretoriuskop/96/4 (Pr4) (Kleiboeker et al.,
1998). Recombinant Pr4 mutants strains Pr4Δ35, Pr4Δ3-C1,Pr4Δ3-C2, Pr4Δ5-1, Pr4Δ5-2 have been described previously
(Burrage et al., 2004) and were a kind gift of Laslo Zsak and John
Neilan (Plum Island Animal Disease Center). ASFV strains were
grown in primary porcine bone marrow cells and mock inoculum
were prepared from uninfected cells. Suid herpesvirus 1 (SuHV-1)
was grown in Vero cells.4.5. Animal experiments
All experiments were carried out under Home Ofﬁce license
PPL 70/7198 which was approved by the Ethical Review Commit-
tee of The Pirbright Institute. Three outbred Large White-Landrace
pigs weighing approximately 20 kg were inoculated intramuscu-
larly with 104 HAD50 of virulent Georgia 2007/1 (animal numbers
AP55 to AP57). Pigs inoculated intramuscularly with 104 HAD50 of
virulent OUR T88/1 (animal numbers AP19 to AP21) have been
described previously (Abrams et al., 2013). Six NIH minipigs of
swine leucocyte antigen (SLA) CC and DD haplotypes (SPF free)
weighing between 18 and 44 kg were inoculated intramuscularly
with 104 TCID50 of low virulent OUR T88/3 (Animal numbers C924,
C926, C927, D784, D787 and D792).4.6. IFNα treatment
Porcine alveolar macrophages were pretreated for 24 h with
2000 IU/ml of recombinant porcine IFNα1 (PBL Interferon Source).
Virus inoculumwas diluted in serum free media and then added to
cells at a multiplicity of infection (MOI) of 0.1. After 90 min at 37 °C
with 5% CO2, the inoculum was removed and cells were washed
with Ca/Mg-free PBS three times. Infection was stopped after 48 h
and the cells underwent one freeze/thaw cycle at 80 °C before
virus titres were determined by end-point dilution in alveolar
macrophages. Logarithmic virus titres were then calculated using
the Spearman and Kärber method. Levels of virus in the blood of
infected pigs were determined using quantitative PCR as described
previously (King et al., 2011).4.7. Detection of biologically active IFN
MDBKt2 cells, in which the chloramphenicol acetyltransferase
(CAT) gene is under the control of the human MxA promoter (Fray
et al., 2001) were used to determine the presence of biologically
active IFN. A two-fold serial dilution of recombinant porcine IFNα1
(range 1000 IU/ml to 7.5 IU/ml) was tested in duplicate and used
as a reference to determine the level of IFN present in serum
derived from ASFV-infected pigs. A media only control was
included. The expression of CAT was determined by ELISA (Roche).4.8. Detection of IFNα and IFNβ
Solid sandwich ELISA detecting porcine IFNα has been descri-
bed previously (Diaz de Arce et al., 1992). Brieﬂy monoclonal anti-
IFNα antibodies K9 (PBL interferon source) and F17 (PBL interferon
source), were used as antigen capture and detecting antibodies,
respectively. The K9 antibody was diluted to 5 μg/ml in carbonate/
bicarbonate buffer and F17 antibody was labelled with biotin. TMB
core substrate (AbDserotec, Bio-Rad) was added and developed for
10 min at room temperature. The reaction was terminated by the
addition of 100 μl of 1 M H2SO4, and absorbance read at 492 nm.
The level of IFNβ was determined using a porcine IFNβ ELISA kit
(Cusabio).
J.P. Golding et al. / Virology 493 (2016) 154–1611604.9. Depletion of CD3þ , CD14þ and CD21þ from PBMCs and infec-
tion with ASFV
PBMCs were puriﬁed from citrated blood derived from three
Babraham in-bred Large-white pigs by centrifugation over histopaque
gradients. 3108 PBMCs were incubated at 4 °C for 15 min in an
antibody mixture containing anti-CD3, anti-CD21 and anti-CD14 in 5%
FCS/PBS. After washing twice in Ca/Mg-free PBS, anti-mouse IgG1 and
anti-mouse IgG2 beads (MACS Miltenyl Biotec) were added and
incubated and washed as before. The cells were passed through LS
columns (MACS Miltenyi Biotec) and the ﬂow-through was collected.
After centrifugation, the cells were resuspended in DMEMþHEPES
supplemented with 10% pig serum, 100 mg/ml streptomycin and
100 U/ml penicillin to a density of 5106 cells/well. Cells were
infected with ASFV strains OUR T88/1 and OUR T88/3 at an MOI of
1 or mock infected. CpG ODN 2216 (InvivoGen) at a ﬁnal concentration
of 3.2 mg/ml or 2 hemagglutination units of Sendai virus (Charles River
Laboratories International) were added as positive controls. Biologi-
cally active IFN was determined from cell supernatants 24 hours post
infection using the MxCAT assay (Fray et al., 2001). The mock inocu-
lum and the two ASFV strains were also tested for their ability to
induce CAT expression in the MDBKt2 cells in the absence of the
negatively-selected PBMCs.
4.10. Statistical analysis
Statistical analysis was carried out using Minitab 16 statistical
analysis programme, where a one-way ANOVA was carried out
with Tukey's post-hoc test when a difference was observed.Acknowledgements
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